Literature DB >> 7574533

Protection of mice from Mycobacterium avium infection by recombinant interleukin-12.

K Kobayashi1, T Kasama, J Yamazaki, M Hosaka, T Katsura, T Mochizuki, K Soejima, R M Nakamura.   

Abstract

Treatment with interleukin-12 (IL-12) significantly reduced the number of viable bacteria in mice infected with Mycobacterium avium. IL-12 itself, however, could not inhibit directly mycobacterial growth in vitro. IL-12 exerts antimycobacterial activity in vivo with a low level of toxicity, possibly by enhancing the host defense against the infection.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7574533      PMCID： PMC162744          DOI： 10.1128/AAC.39.6.1369

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

Review 1.  Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis.

Authors:  A M Dannenberg
Journal:  Immunol Today       Date:  1991-07

Review 2.  Immunity to intracellular bacteria.

Authors:  S H Kaufmann
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

3.  Progress in TB research: Robert Koch's dilemma revisited.

Authors:  S Ehlers; M E Mielke; H Hahn
Journal:  Immunol Today       Date:  1994-01

4.  Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts.

Authors:  R T Gazzinelli; S Hieny; T A Wynn; S Wolf; A Sher
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

5.  Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates.

Authors:  M Denis
Journal:  Cell Immunol       Date:  1991-01       Impact factor: 4.868

6.  Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model.

Authors:  L E Bermudez; J Martinelli; M Petrofsky; P Kolonoski; L S Young
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

7.  Resistance to nitric oxide in Mycobacterium avium complex and its implication in pathogenesis.

Authors:  T Doi; M Ando; T Akaike; M Suga; K Sato; H Maeda
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

Review 8.  Interleukin-12.

Authors:  M J Brunda
Journal:  J Leukoc Biol       Date:  1994-02       Impact factor: 4.962

9.  Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response.

Authors:  J P Sypek; C L Chung; S E Mayor; J M Subramanyam; S J Goldman; D S Sieburth; S F Wolf; R G Schaub
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

10.  Recombinant interleukin 12 cures mice infected with Leishmania major.

Authors:  F P Heinzel; D S Schoenhaut; R M Rerko; L E Rosser; M K Gately
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307
View more
  10 in total

Review 1.  Pathogenesis of Mycobacterium avium infection: typical responses to an atypical mycobacterium?

Authors:  Rui Appelberg
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase.

Authors:  T Hayashi; S P Rao; K Takabayashi; J H Van Uden; R S Kornbluth; S M Baird; M W Taylor; D A Carson; A Catanzaro; E Raz
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

3.  Inhibition of tumor necrosis factor alpha alters resistance to Mycobacterium avium complex infection in mice.

Authors:  S Bala; K L Hastings; K Kazempour; S Inglis; W L Dempsey
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  T-cell-independent granuloma formation in response to Mycobacterium avium: role of tumour necrosis factor-alpha and interferon-gamma.

Authors:  D Smith; H Hänsch; G Bancroft; S Ehlers
Journal:  Immunology       Date:  1997-12       Impact factor: 7.397

5.  Immunomodulatory role of endogenous interleukin-18 in gamma interferon-mediated resolution of replicative Legionella pneumophila lung infection.

Authors:  J K Brieland; C Jackson; S Hurst; D Loebenberg; T Muchamuel; R Debets; R Kastelein; T Churakova; J Abrams; R Hare; A O'Garra
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

6.  Role of CD40 ligand in Mycobacterium avium infection.

Authors:  T Hayashi; S P Rao; P R Meylan; R S Kornbluth; A Catanzaro
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

7.  In vivo regulation of replicative Legionella pneumophila lung infection by endogenous interleukin-12.

Authors:  J K Brieland; D G Remick; M L LeGendre; N C Engleberg; J C Fantone
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

Review 8.  Interleukin-12 in infectious diseases.

Authors:  L Romani; P Puccetti; F Bistoni
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

9.  Interleukin-12 and host defense against murine Pneumocystis pneumonia.

Authors:  Sanbao Ruan; Laura McKinley; Mingquan Zheng; Xiaowen Rudner; Alain D'Souza; Jay K Kolls; Judd E Shellito
Journal:  Infect Immun       Date:  2008-03-10       Impact factor: 3.441

Review 10.  The Rise of Non-Tuberculosis Mycobacterial Lung Disease.

Authors:  Champa N Ratnatunga; Viviana P Lutzky; Andreas Kupz; Denise L Doolan; David W Reid; Matthew Field; Scott C Bell; Rachel M Thomson; John J Miles
Journal:  Front Immunol       Date:  2020-03-03       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.